Paratek Pharmaceuticals, Inc. (PRTK - Free Report) was a big mover last session, as the company saw its shares rise nearly 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, trading within a volatile range of $9.05–$10.20 in the past one-month time frame, showed a sharp increase yesterday.
The stock was driven after the company obtained the FDA approval for Nuzyra to treat community-acquired bacterial pneumonia (CABP) and acute skin infections.
The company has seen no changes when it comes to estimate revision over the past month, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Paratek Pharmaceuticals currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.
A better-ranked stock in the Medical – Biomedical and Genetics industry is Caladrius Biosciences, Inc. (CLBS - Free Report) , which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is PRTK going up? Or down? Predict to see what others think: Up or Down
5 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2018 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs. A bonus Zacks Special Report names this breakthrough and the 5 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains.
Click to see them right now >>